Form 8-K · Current report
Ametek 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0001037868
- Accession no.
- 0001037868-26-000173
Summary
AMETEK reported record second-quarter 2026 sales of $2.04 billion, up 15% from a year earlier, with GAAP diluted earnings of $1.77 per share and adjusted earnings of $2.09 per share, and raised its full-year 2026 adjusted earnings guidance to $8.20–$8.30 per share from a prior range of $7.94–$8.14. Chairman and CEO David A. Zapico attributed the results to organic sales growth, recent acquisitions and operating performance, and said orders grew 28% in the quarter, with notable strength in semiconductor, commercial aerospace, medtech, defense and automation markets.
Key points
- Second-quarter 2026 sales were $2.04 billion, up 15% year over year; GAAP operating income was $528.2 million and adjusted operating margin was 26.6%.
- Electronic Instruments Group sales rose 14% to $1.32 billion and Electromechanical Group sales rose 17% to a record $723.2 million.
- Third-quarter 2026 sales are expected to be up high single digits year over year, with adjusted earnings of $2.08–$2.10 per share, and full-year 2026 sales are expected to be up about 10%.
- Operating cash flow in the quarter rose 35% to $483.7 million, with free cash flow to net income conversion of 111%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 4, 2026, AMETEK, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the release is furnished as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished pursuant to Item 2.02 of Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.